PMID- 28063195
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20220311
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Linking)
VI  - 119
IP  - 6
DP  - 2017 Jun
TI  - First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic 
      castration-resistant prostate cancer: a systematic review of 10 randomised 
      clinical trials.
PG  - 831-845
LID - 10.1111/bju.13764 [doi]
AB  - The aim of this study is to systematically evaluate all available treatment 
      options in chemotherapy-naive patients with metastatic castration-resistant 
      prostate cancer (mCRPC). We systematically searched PubMed, EMBASE, and the 
      Cochrane libraries up to 1 March 2016 for peer-reviewed publications on 
      randomised clinical trials (RCTs). RCTs were included if progression-free 
      survival (PFS), overall survival (OS), quality of life (QoL), or adverse events 
      (AEs) were quantitatively evaluated. We assessed the risk of bias with the 
      Cochrane Collaboration's tool and graded the evidence with the Grading of 
      Recommendations Assessment, Development and Evaluation (GRADE) Working Group's 
      approach. We included 25 articles, reporting on 10 unique RCTs describing seven 
      different comparisons. In one RCT, a prolonged OS and PFS (high quality) were 
      found with abiraterone and prednisone compared to placebo plus prednisone. In one 
      RCT, a prolonged OS and PFS (high quality) were found with enzalutamide compared 
      to placebo. In two RCTs, a prolonged OS (high and moderate quality) was found 
      with (223) radium compared to placebo, but its effect on PFS is unknown. In three 
      RCTs, a prolonged OS (moderate quality) was found with sipuleucel-T compared to 
      placebo, but no prolonged PFS (low quality). In one RCT a prolonged PFS (high 
      quality) was found with orteronel compared to placebo, but no prolonged OS 
      (moderate quality). In one RCT, a prolonged OS (moderate quality) was found with 
      bicalutamide compared to placebo, but its effect on PFS is unknown. In one RCT, a 
      prolonged PFS (high quality) was found with enzalutamide compared to 
      bicalutamide, but its effect on OS is unknown. The best evidence was found for 
      abiraterone and enzalutamide for effective prolongation of OS and PFS to treat 
      chemotherapy-naive patients with mCRPC. However, taking both QoL and AEs into 
      consideration, other treatment modalities could be considered for individual 
      patients.
CI  - (c) 2017 The Authors BJU International (c) 2017 BJU International Published by John 
      Wiley & Sons Ltd.
FAU - Poorthuis, Michiel H F
AU  - Poorthuis MHF
AUID- ORCID: 0000-0001-5198-2823
AD  - Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), 
      Utrecht, The Netherlands.
FAU - Vernooij, Robin W M
AU  - Vernooij RWM
AUID- ORCID: 0000-0001-5734-4566
AD  - Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), 
      Utrecht, The Netherlands.
FAU - van Moorselaar, R Jeroen A
AU  - van Moorselaar RJA
AUID- ORCID: 0000-0002-2559-9254
AD  - Department of Urology, VU University Medical Center, Amsterdam, The Netherlands.
FAU - de Reijke, Theo M
AU  - de Reijke TM
AUID- ORCID: 0000-0003-0651-7361
AD  - Department of Urology, Academic Medical Center, Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20170228
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
SB  - IM
MH  - Disease-Free Survival
MH  - Humans
MH  - Male
MH  - Neoplasm Metastasis
MH  - Prostatic Neoplasms, Castration-Resistant/*drug therapy/pathology
MH  - Randomized Controlled Trials as Topic
MH  - Survival Rate
OTO - NOTNLM
OT  - docetaxel-naive
OT  - metastatic castration-resistant prostate cancer
OT  - overall survival
OT  - progression-free survival
OT  - prostate-specific antigen
EDAT- 2017/01/08 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/01/08 06:00
PHST- 2017/01/08 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
PHST- 2017/01/08 06:00 [entrez]
AID - 10.1111/bju.13764 [doi]
PST - ppublish
SO  - BJU Int. 2017 Jun;119(6):831-845. doi: 10.1111/bju.13764. Epub 2017 Feb 28.